Oral and Non-Oral Cholesterol-Lowering Drugs with PCSK9 and Other Biomolecules as Targets: Present Status and Future Prospects
The accumulation of high levels of cholesterol associated with low-density lipoprotein (LDL) in the bloodstream is the key risk factor for stroke and cardiovascular diseases. Therefore, reducing the concentration of LDL-cholesterol in the blood and maintaining it at an optimum level are vital especi...
Saved in:
| Main Author: | Ajoy Basak |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/15/4/468 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PCSK9 Inhibitors: The Evolving Future
by: Bijay Mukesh Jeswani, et al.
Published: (2024-11-01) -
The role of proprotein convertase subtilisin/kexin type 9 inhibitors in managing cardiovascular risk
by: Natalie Schellack, et al.
Published: (2016-01-01) -
ASSOCIATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WITH HYPERTENSION AND SMOKING
by: K. S. Benimetskaya, et al.
Published: (2019-03-01) -
Levels of proprotein convertase subtilisin/kexin type 9 in patients with acute myocardial infarction
by: A. D. Gimadeeva, et al.
Published: (2020-03-01) -
The importance of paying attention to the role of lipid-lowering drugs in controlling dengue virus infection
by: Omer Qutaiba B. Allela, et al.
Published: (2024-12-01)